The ZUMA-24 phase II clinical trial demonstrates the safety and feasibility of administering Yescarta (axi-cel) in the outpatient setting when treating relapsed or refractory large B-cell lymphoma.Â
Researchers from UVA Cancer Center, the University of Virginia School of Medicine, and Inova Peterson Life with Cancer detail the many ways artificial intelligence could help ensure patients receive the support they need.
A novel method could test for prostate cancer using biomarkers present in urine, according to the findings from a diagnostic case control study.
When it comes to their survival, cancer cells have a host of backup plans.
Rybrevant (amivantamab-vmjw) + Lazcluze (lazertinib) demonstrated a statistically significant and clinically meaningful overall survival improvement for patients with previously untreated locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or L858R substitution mutations, according to data from the phase III Mariposa study.
Tagrisso (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of OS compared to Tagrisso monotherapy in the 1st-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer.Â
Pacdev (enfortumab vedotin), in combination with PD-1 inhibitor Keytruda (pembrolizumab), reached the main goals in a late-stage trial for certain patients with bladder cancer.
NeXT Personal, a highly sensitive molecular residual disease test, is a strong predictor of outcomes in patients with stage II-IIIb, EGFR-mutated non-small cell lung cancer receiving neoadjuvant therapy, according to data from NeoADAURA phase III clinical trial run by AstraZeneca.Â
Immune-checkpoint therapy, which attempts to harness a patient’s own immune system to fight cancer, has revolutionized cancer care over the past two decades.Â
A novel treatment approach using combination immunotherapy before and after surgery shows promise for patients with operable mesothelioma, according to a new study led by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg Kimmel Institute for Cancer Immunotherapy.Â
